SCHEMBL424620

SCHEMBL424620

Cc1c(-c2ccccc2)ncn1C(=O)N(C)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
CNR1 P21554 1/20 0.46
LIPE Q05469 1/20 0.45
APOBEC3A P31941 1/20 0.45
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
CA12 O43570 1/20 0.44
CA9 Q16790 1/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 1/20 0.44
ALDH1A1 P00352 1/20 0.44
HRH3 Q9Y5N1 1/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL425793 0.73 TRPV1 (0.47) LMNALIPENPC1RAB9AALDH1A1
SCHEMBL24937720 0.68 NPC1 (0.54) LMNALIPEAPOBEC3ANPC1RAB9A
SCHEMBL18515882 0.67 NPC1 (0.58) LIPENPC1RAB9ACA12CA9
SCHEMBL180384 0.67 NPC1 (0.73) NPC1RAB9ACA12CA9KMT2A
SCHEMBL14937537 0.67 FAAH (0.58) LMNAAPOBEC3AKMT2AMEN1ALDH1A1
SCHEMBL5648204 0.67 CYP1A2 (0.51) LMNAAPOBEC3ANPC1RAB9ACA12
Hydrochloric Acid SCHEMBL11786759 0.66 NPC1 (0.70) NPC1RAB9ACA12CA9KMT2A
SCHEMBL3095761 0.66 NPC1 (0.70) LMNANPC1RAB9ACA12CA9
SCHEMBL18485384 0.65 NPC1 (0.54) LIPENPC1RAB9ACA12CA9
SCHEMBL26763845 0.64 HPGD (0.68) LMNANPC1RAB9ACA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 LMNA 2523/4885CNR1 15/4885LIPE 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.